Novartis' Aimovig prevents migraines in patients who failed prior treatment in Phase IIIb

Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) said Aimovig erenumab met the primary and all secondary endpoints in the Phase IIIb LIBERTY trial to prevent episodic migraine in patients who failed two to four previous prophylactic treatments. The partners

Read the full 400 word article

User Sign In